Regulators need to know the manufacturing process is under control, but the EU guideline does not require every product to be validated in the same way at the time of submission.
What the guideline sets out
The EMA guideline on process validation for finished products describes the information and data to be provided in regulatory submissions. It recognises three broad approaches: traditional process validation, continuous process verification and a hybrid of the two.
The choice influences what goes into section 3.2.P.3.5 and what is held in the quality system for inspection.
Traditional approach
Under the traditional approach, validation is generally carried out on a number of consecutive production-scale batches before commercial release. For standard processes and well-established dosage forms, the guideline allows a validation scheme to be submitted with a commitment to complete it, rather than full data on production-scale batches at the time of filing, provided the applicant can justify the approach.
For non-standard processes, such as certain sterile or modified-release products, or where the process is critical to quality, production-scale data are normally expected at submission.
Continuous process verification
Where development knowledge is extensive and the process is monitored by suitable in-line or on-line measurements, ongoing verification can replace or supplement discrete validation batches. The dossier should show the control strategy, the critical process parameters and quality attributes, and how process performance will be monitored and trended.
This route relies heavily on pharmaceutical development under ICH Q8 and on the quality system principles of ICH Q10.
What reviewers look for
- A clear description of the manufacturing process, including critical steps and in-process controls.
- Justification of batch size and equipment, with scale-up reasoning.
- For sterile products, evidence of sterilisation validation and aseptic process simulation.
- A realistic validation scheme or protocol with predefined acceptance criteria.
- Consistency between the process in the dossier and the process used on the shop floor.
Linking to the site
The dossier and the GMP file tell two sides of the same story. If the validation approach in Module 3 differs from the site validation master plan, an inspector will notice it, and so will an assessor if a variation follows.
Questions to ask before filing
Is the validation scheme defined with acceptance criteria and a clear commitment on timing? Are batch sizes at the proposed commercial scale or justified bridging? Do equipment trains in the dossier match those on site? If a site transfer is planned after approval, consider how the validation package will be reused, because comparability data are often requested by authorities in that situation.
How PQRA helps
PQRA helps applicants decide how much process validation information to place in the dossier, reviews validation schemes and protocols, and checks that Module 3 and manufacturing site documentation tell the same story.
Talk to us about your dossier: Contact PQRA


No responses yet